Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- SARS CoV-2 Infection
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: Main randomization. Patients will be randomized to Emtricitabine / Tenofovir disoproxil fumarate or no treatment. Rescue randomization: patients with oxygen requirements, O2 Sat <95% at any time, and at least one of the following inflammation markers: IL-6, CRP, D-dimer, LDH or ferritin above the upper limit of the normal range. Arms: dexamethasone + Baricitinib dexamethasone Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04890626
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon